Created On: 2020-07-15
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 257618
Upon the exercise of the Scenario II Option, The Swiss Licensee shall take over the lnvestigational New Drug Application with the FDA or such other application filed with any other Regulatory Authority and Licensee shall be responsible for the overall development and regulatory filings for the Product in the Territory. Subject only to the option to co-promote under Scenario II Licensee and its Affiliates shall have the exclusive rights for the Commercialization of the Compound or Product and Licensor shall grant Licensee an exclusive license under the Licensor Technology.
Upon the exercise of the Scenario III Option. In the event that Licensee does not exercise its Scenario II Option, Licensor will consider the results of the Phase II Clinical Trial and may elect to commence Phase III Clinical Trials for the Product within twelve months of the delivery of the final Phase II Clinical Trial report to Licensee. Subject only to the option to co-promote under Scenario Ill Licensee and its Affiliates shall have the exclusive rights for the Commercialization of the Compound or Product and Licensor shall grant Licensee and exclusive license under the Licensor Technology.
IPSCIO Record ID: 257487
Subject to the Scenario II Option and Scenario III Option and the Co-Promotion Option being exercised by Licensor, Licensee shall have an exclusive license to Commercialize the Compound and Product, with right to sublicense without consent.
VSF-173 is a compound for the treatment of excessive sleepiness, for which we expect to begin a Phase II trial in the second half of 2006
IPSCIO Record ID: 223128
Compound shall mean the compound currently identified by Licensors as NDD-094 or isomers or epimers thereof and any metabolites and salts thereof and more particularly described Licensor Patents shall mean those Patents Controlled by Licensor claiming Compound, Product, or their metabolites or any formulation of Compound, processes, uses and intermediates of the foregoing.
Licensor Know-How shall mean any proprietary or nonproprietary information specific to the Compound or Product within the Field of Use and of a confidential nature necessary or useful for the manufacture, preparation or development of the Compound or Product Controlled by Licensors during the term of this Agreement and shall include, without limitation, data, knowledge and information., including chemical, stability, pharmacological, toxicological, pre-clinical, clinical and manufacturing data, samples, documentation, analytical standards, and gene expression data.
Patents – United States
5,635,521 – Imidazolylmethyl-pyridines
5,856,343 – Imidazolylmethyl-pyridines used for senile dementia
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia.